JUST IN: @US_FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell carcinoma (RCC) following PD1 and VEGF inhibitors! A great day for the field and a new option for our Kidney Cancer patients!!!! Via @ASCO #FDAAlerts @OncoAlert Study presented at @myESMO #ESMO3 by @AlbigesL
@DrChoueiri @US_FDA @ASCO @OncoAlert @myESMO @DanaFarber @DanaFarberNews @DanaFarber_GU @tompowles1 @Uromigos @neerajaiims @montypal @AlbigesL @brian_rini @DrRanaMcKay Awesome news, still wondering whether somatic VHL subgroup will have any better response to belzutifan..( doesnt appear to be the case )
@DrChoueiri @US_FDA @ASCO @OncoAlert @myESMO @DanaFarber @DanaFarberNews @DanaFarber_GU @tompowles1 @Uromigos @neerajaiims @montypal @AlbigesL @brian_rini @DrRanaMcKay Amazing, simply great news for all metastatic kidney cancer patients. Congrats @DrChoueiri @tompowles1 @AlbigesL @brian_rini @Katriinapeltol1 and all other scientists involved in the conduction of this landmark trial leading to fast FDA approval.
@DrChoueiri @US_FDA @ASCO @OncoAlert @myESMO @DanaFarber @DanaFarberNews @DanaFarber_GU @tompowles1 @Uromigos @neerajaiims @montypal @AlbigesL @brian_rini @DrRanaMcKay Love my Belzutifan. #Litespark-003
@DrChoueiri @US_FDA @ASCO @OncoAlert @myESMO @DanaFarber @DanaFarberNews @DanaFarber_GU @tompowles1 @Uromigos @neerajaiims @montypal @AlbigesL @brian_rini @DrRanaMcKay Great news! Remember fighting with insurance last year for belzutifan approval… ASCO poster was not enough…
@DrChoueiri @US_FDA @ASCO @OncoAlert @myESMO @DanaFarber @DanaFarberNews @DanaFarber_GU @tompowles1 @Uromigos @neerajaiims @montypal @AlbigesL @brian_rini @DrRanaMcKay Another great news for RCC patients
@DrChoueiri @US_FDA @ASCO @OncoAlert @myESMO @DanaFarber @DanaFarberNews @DanaFarber_GU @tompowles1 @Uromigos @neerajaiims @montypal @AlbigesL @brian_rini @DrRanaMcKay #GUcanceroncrhistmas astonishing approval results provide by the FDA, let’s wait same approval in our regulatory agencies, great advance for RCC patients! Congrats @DrChoueiri @AlbigesL @OncoAlert @urotoday @UroTarget @SCUoncolombia @achoHematoYOnco @ACHOCol